PD-L1 expression as a predictive biomarker in cancer immunotherapy

Cited by (1,001)

Items 201–300 of 1,001

1. ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance
   Jacob J. Orme, Khalid Jazieh, Tiancheng Xie, Susan M. Harrington, Xin Liu, Matthew K. Ball, Benjamin J. Madden, M. Cristine Charlesworth, Tariq U. Azam, Fabrice Lucien et al. · 2020 · OncoImmunology
2. Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression
   Maria Tretiakova, Regan S. Fulton, Masha Kocherginsky, Thomas H. Long, Cigdem Ussakli, Tatjana Antic, Allen M. Gown · 2017 · Modern Pathology
3. Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)
   Lorena Incorvaia, Daniele Fanale, Giuseppe Badalamenti, Nadia Barraco, Marco Bono, Lidia Rita Corsini, Antonio Galvano, Valerio Gristina, Angela Listì, Salvatore Vieni et al. · 2019 · Advances in Therapy
4. Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors
   Yu Mei, Wenya Linda Bi, Noah F. Greenwald, Ziming Du, Nathalie Y.R. Agar, Ursula B. Kaiser, Whitney W. Woodmansee, David A. Reardon, Gordon James Freeman, Peter Edward Fecci et al. · 2016 · Oncotarget
5. Role of immune-checkpoint inhibitors in lung cancer
   Prantesh Jain, Chhavi Jain, Vamsidhar Velcheti · 2018 · Therapeutic Advances in Respiratory Disease
6. Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade
   Natalie Galanina, Aaron Michael Goodman, Philip R Cohen, Garrett Michael Frampton, Razelle Kurzrock · 2018 · Cancer Immunology Research
7. Comprehensive Immune Monitoring of Clinical Trials to Advance Human Immunotherapy
   Hartmann, Felix J., Babdor, Joel, Gherardini, Pier Federico, Amir, El-Ad D., Jones, Kyle, Sahaf, Bita, Marquez, Diana M., Krutzik, Peter, O’Donnell, Erika, Sigal, Natalia et al. · 2019 · Cell Reports
8. 89Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer
   Christopher G. England, Dawei Jiang, Emily B. Ehlerding, Brian T. Rekoske, Paul A. Ellison, Reinier T. Hernandez, Todd E. Barnhart, Douglas G. McNeel, Peng Huang, Weibo Cai · 2017 · European Journal of Nuclear Medicine and Molecular Imaging
9. NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1
   Xiaozhen Zhang, Xing Huang, Jian Xu, Enliang Li, Mengyi Lao, Tianyu Tang, Gang Zhang, Chengxiang Guo, Xiaoyu Zhang, Wen Chen et al. · 2021 · Nature Communications
10. 5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers
    Lauren Van Der Kraak, Gaurav Goel, Krishnaveni Ramanan, Christof Kaltenmeier, Lin Zhang, Daniel Paul Normolle, Gordon James Freeman, Daolin Tang, Katie Sue Nason, Jon M. Davison et al. · 2016 · Journal for ImmunoTherapy of Cancer
11. A phase II basket trial of Dual Anti–CTLA–4 and Anti–PD–1 Blockade in Rare Tumors (DART) SWOG S1609: High‐grade neuroendocrine neoplasm cohort
    Sandip Pravin Patel, Edward Mayerson, Young Kwang Chae, Jonathan Strosberg, Jue Wang, Bhavana Konda, Jourdain Hayward, Christine M. McLeod, Helen X. Chen, Elad Sharon et al. · 2021 · Cancer
12. Extracellular vesicles remodel tumor environment for cancer immunotherapy
    Ming Yue, Shengyun Hu, Haifeng Sun, Baojing Tuo, Bin Jia, Chen Chen, Wenkang Wang, Jinbo Liu, Yang Liu, Zhenqiang Sun et al. · 2023 · Molecular Cancer
13. Tissue and Blood Biomarkers in Lung Cancer: A Review
    Michael Joe Duffy, Kenneth John O'Byrne · 2018 · Advances in clinical chemistry
14. A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone
    Julie Nicole Graff, Tomasz M. Beer, Joshi J. Alumkal, Rachel Slottke, William L. Redmond, GEORGE V. THOMAS, Reid F. Thompson, Mary Ann Wood, Yoshinobu Koguchi, Yiyi Chen et al. · 2020 · Journal for ImmunoTherapy of Cancer
15. Subgroup-specific immune and stromal microenvironment in medulloblastoma
    Bockmayr, Michael, Mohme, Malte, Klauschen, Frederick, Winkler, Beate, Budczies, Jan, Rutkowski, Stefan, Schüller, Ulrich · 2018 · OncoImmunology
16. PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma
    Naoya Maekawa, Satoru Konnai, Maki Nishimura, Yumiko Kagawa, Satoshi Takagi, Kenji Hosoya, Hiroshi Ohta, Sangho Kim, Tomohiro Okagawa, Yusuke Izumi et al. · 2021 · npj Precision Oncology
17. Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma
    Stefan Klaus Barta, Jasmine M. Zain, Alexander W. Macfarlane, Sonali M. Smith, Jia Ruan, Henry C.H. Fung, Carlyn Rose C. Tan, Yibin Yang, R. Katherine Alpaugh, Essel Dulaimi et al. · 2019 · Clinical Lymphoma Myeloma & Leukemia
18. Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4
    Pratibha Pandey, Fahad Khan, Huda A. Qari, Tarun Kumar Upadhyay, Abdulhameed Fouad Alkhateeb, Mohammad Oves · 2022 · Pharmaceuticals
19. Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies
    Woo Young Sun, Yu Kyung Lee, Ja Seung Koo · 2016 · Journal of Translational Medicine
20. Cancer CRISPR Screens In Vivo
    Ryan Dz-Wei Chow, Sidi Chen · 2018 · Trends in cancer
21. Integrin αvβ3-targeted radionuclide therapy combined with immune checkpoint blockade immunotherapy synergistically enhances anti-tumor efficacy
    Haojun Chen, Liang Zhao, Kaili Fu, Qiuming Lin, Xuejun Wen, Orit Jacobson, Long Sun, Hua Wu, Xianzhong Zhang, Zhide Guo et al. · 2019 · Theranostics
22. Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer
    Diego de Miguel‐Pérez, Alessandro Russo, Oscar G. Arrieta, Murat Ak, Feliciano Barrón, Muthukumar Gunasekaran, Priyadarshini Mamindla, Luis Lara‐Mejía, Christine B. Peterson, Mehmet Emin Er et al. · 2022 · Journal of Experimental & Clinical Cancer Research
23. Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness
    Robby Barnestein, Loïck Galland, Laura Kalfeist, François Ghiringhelli, Sylvain Ladoire, Emeric Limagne · 2022 · OncoImmunology
24. Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy
    Shui, Lin, Yang, Xi, Li, Jian, Yi, Cheng, Sun, Qin, Zhu, Hong · 2020 · Frontiers in Immunology
25. Checkpoint blockade in the treatment of breast cancer: current status and future directions
    Lironne Wein, Stephen J. Luen, Peter Stephen Savas, Roberto Salgado, Sherene Loi · 2018 · British Journal of Cancer
26. Triple‑negative breast cancer: A run‑through of features, classification and current therapies (Review)
    Meghana Manjunath, Bibha Choudhary · 2021 · Oncology Letters
27. Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma
    Robert John Motzer, Toni K. Choueiri, David F. McDermott, Thomas B. Powles, Yann Alexandre Vano, Saurabh Kumar Gupta, Jin Yao, G. Celine Han, Ron Ammar, Simon Papillon‐Cavanagh et al. · 2022 · Journal for ImmunoTherapy of Cancer
28. A Dual‐Responsive STAT3 Inhibitor Nanoprodrug Combined with Oncolytic Virus Elicits Synergistic Antitumor Immune Responses by Igniting Pyroptosis
    Wen Su, Wei Qiu, Shu‐Jin Li, Shuo Wang, Jun Xie, Qi‐Chao Yang, Jiming Xu, Junjie Zhang, Zhigang Xu, Zhi‐Jun Sun · 2022 · Advanced Materials
29. Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging
    Aaron T. Mayer, Arutselvan Natarajan, Sydney R. Gordon, Roy L. Maute, Melissa N. McCracken, Aaron M. Ring, Irving L. Weissman, Sanjiv Sam Gambhir · 2016 · Journal of Nuclear Medicine
30. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non‐small cell lung cancer
    Ilaria Alborelli, Katharina Leonards, Sacha I. Rothschild, Laura P Leuenberger, Spasenija Savic Prince, Kirsten D. Mertz, Severin Poechtrager, Martin Buess, Alfred Zippelius, Heinz Philipp Laubli et al. · 2019 · The Journal of Pathology
31. ICOS Is an Indicator of T-cell–Mediated Response to Cancer Immunotherapy
    Zunyu Xiao, Aaron T. Mayer, Tomomi W. Nobashi, Sanjiv Sam Gambhir · 2020 · Cancer Research
32. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non–Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
    Young Kwang Chae, Alan P. Pan, Andrew A. Davis, Kirtee Raparia, Nisha Anjali Mohindra, Maria Matsangou, Francis Joseph Giles · 2016 · Clinical Lung Cancer
33. Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center
    Andrew B. Sharabi, Sangwoo Shawn Kim, Shumei Kato, P. Dominick Sanders, Sandip Pravin Patel, Parag R. Sanghvi, Elizabeth Weihe, Razelle Kurzrock · 2017 · The Oncologist
34. Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading
    Elisabetta Cavalcanti, Raffaele Armentano, Anna Maria Valentini, Marcello Chieppa, Maria Lucia Caruso · 2017 · Cell Death and Disease
35. PD-1/PD-L1 pathway inhibitors in advanced prostate cancer
    Pedro Isaacsson Velho, Emmanuel S. Antonarakis · 2018 · Expert Review of Clinical Pharmacology
36. PD-L1 expression in non-small cell lung cancer: correlations with genetic alterations
    Scheel, Andreas H., Ansén, Sascha, Schultheis, Anne M., Scheffler, Matthias, Fischer, Rieke N., Michels, Sebastian, Hellmich, Martin, George, Julie, Zander, Thomas, Brockmann, Michael et al. · 2016 · OncoImmunology
37. Expression of Programmed Death Ligand 1 in Penile Cancer is of Prognostic Value and Associated with HPV Status
    Sarah R. Ottenhof, Rosa S. Djajadiningrat, Jeroen de Jong, Helene Hoegsbro Thygesen, Simon Horenblas, Ekaterina S. Jordanova · 2016 · The Journal of Urology
38. Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents
    Paola Ciciola, Priscilla Cascetta, Cataldo Bianco, Luigi Formisano, Roberto Bianco · 2020 · Journal of Clinical Medicine
39. A Low Tumor Mutational Burden and <i>PTEN</i> Mutations Are Predictors of a Negative Response to PD-1 Blockade in MSI-H/dMMR Gastrointestinal Tumors
    Chida, Keigo, Kawazoe, Akihito, Kawazu, Masahito, Suzuki, Toshihiro, Nakamura, Yoshiaki, Nakatsura, Tetsuya, Kuwata, Takeshi, Ueno, Toshihide, Kuboki, Yasutoshi, Kotani, Daisuke et al. · 2021 · Clinical Cancer Research
40. Next generation predictive biomarkers for immune checkpoint inhibition
    Yulian Khagi, Razelle Kurzrock, Sandip Pravin Patel · 2016 · Cancer and Metastasis Reviews
41. Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC)
    Sabine Schmid, Stefan Diem, Qiyu Li, Mirjam Krapf, Lukas Flatz, Sebastian Leschka, Lotus May Desbiolles, Dirk Klingbiel, Wolfram Jochum, Martin Früh · 2018 · Cancer Immunology Immunotherapy
42. Basis of PD1/PD-L1 Therapies
    Barbara Seliger · 2019 · Journal of Clinical Medicine
43. Anti–PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection–Related Advanced Hepatocellular Carcinoma: A Literature Review
    Bin Li, Cong Yan, Jiamin Zhu, Xiaobing Chen, Qihan Fu, Hangyu Zhang, Zhou Tong, Lulu Liu, Yi Zheng, Peng Zhao et al. · 2020 · Frontiers in Immunology
44. MHC-I genotype and tumor mutational burden predict response to immunotherapy
    Aaron Michael Goodman, Andrea Castro, Rachel Marty Pyke, Ryosuke Okamura, Shumei Kato, Paul J. Riviere, Garrett Michael Frampton, Ethan S. Sokol, Xinlian Zhang, Edward David Ball et al. · 2020 · Genome Medicine
45. Increased PD ‐L1 expression in breast and colon cancer stem cells
    Yanheng Wu, Mingshui Chen, Peihong Wu, Chen Chen, Zhi Ping Xu, Wenyi Gu · 2017 · Clinical and Experimental Pharmacology and Physiology
46. CCR4 as a Therapeutic Target for Cancer Immunotherapy
    Osamu Yoshie · 2021 · Cancers
47. EBV-associated diseases: Current therapeutics and emerging technologies
    Srishti Chakravorty, Behdad Afzali, Majid Kazemian · 2022 · Frontiers in Immunology
48. Interplay between Immune Checkpoint Proteins and Cellular Metabolism
    Sangbin Lim, Joshua B. Phillips, Luciana Madeira da Silva, Ming Zhou, Øystein Fodstad, Laurie B. Owen, Ming Tan · 2017 · Cancer Research
49. Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy
    Katrijn Broos, Quentin Lecocq, Geert Raes, Nick Devoogdt, Marleen Keyaerts, Karine Breckpot · 2018 · Theranostics
50. Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor
    Joseph Elan Grossman, Divya Vasudevan, Cailin E. Joyce, Manuel Hildago · 2021 · Oncogene
51. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment
    Tian Zhou, Alexander I. Sankin, Steven Anthony Porcelli, David S. Perlin, Mark Schoenberg, Xingxing Zang · 2016 · Urologic Oncology Seminars and Original Investigations
52. Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real‐life analysis of three larger gene panels
    Volker Endris, Ivo Buchhalter, Michael Allgäuer, Eugen Rempel, Amelie Lier, Anna‐Lena Volckmar, Martina Kirchner, Moritz von Winterfeld, Jonas Leichsenring, Olaf Neumann et al. · 2018 · International Journal of Cancer
53. PD-L1 monoclonal antibody-conjugated nanoparticles enhance drug delivery level and chemotherapy efficacy in gastric cancer cells
    Shijie Xu, Fangbo Cui, Dafu Huang, Dinghu Zhang, Anqing Zhu, Xia Sun, Yiming Cao, Sheng Ding, Yao Wang, Eryun Gao et al. · 2018 · International Journal of Nanomedicine
54. Hepatocellular Carcinoma–Circulating Tumor Cells Expressing PD‐L1 Are Prognostic and Potentially Associated With Response to Checkpoint Inhibitors
    Paul Winograd, Shuang Hou, Colin M. Court, Yi‐Te Lee, Pin‐Jung Chen, Yazhen Zhu, Saeed Sadeghi, Richard S. Finn, Pai‐Chi Teng, Jasmin J. Wang et al. · 2020 · Hepatology Communications
55. TRIM28 promotes the escape of gastric cancer cells from immune surveillance by increasing PD-L1 abundance
    Xiaoxiao Ma, Shuqin Jia, Gangjian Wang, Min Liang, Ting Guo, Hong Du, Sisi Li, Xiaomei Li, Longtao Huangfu, Jianping Guo et al. · 2023 · Signal Transduction and Targeted Therapy
56. Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors
    Shan Xie, Jia Huang, Qin Qiao, Wenjuan Zang, Shanjuan Hong, Haidong Tan, Chen Dong, Zhiying Yang, Ling Ni · 2018 · Cancer Immunology Immunotherapy
57. Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients
    Archana Anantharaman, Terence W. Friedlander, David M. Lu, Rachel Krupa, Gayatri Premasekharan, Jeffrey Hough, Matthew Edwards, Rosa Paz, Karla J. Lindquist, Ryon P. Graf et al. · 2016 · BMC Cancer
58. Invasive lobular and ductal breast carcinoma differ in immune response, protein translation efficiency and metabolism
    Tian Du, Li Zhu, Kevin M. Levine, Nilgun Tasdemir, Adrian V. Lee, Dario A.A. Vignali, Bennett Van Houten, George C. Tseng, Steffi Oesterreich · 2018 · Scientific Reports
59. Identification and validation of an anoikis-associated gene signature to predict clinical character, stemness, IDH mutation, and immune filtration in glioblastoma
    Zhongzheng Sun, Yongquan Zhao, Wei Yan, Xuan Ding, Chenyang Tan, Chengwei Wang · 2022 · Frontiers in Immunology
60. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients
    Julia Y. Tsang, W AU, Kwan-Yin Lo, Yun‐Bi Ni, Thazin Hlaing, Jintao Hu, Siu‐Ki Chan, Kui-Fat Chan, Sai‐Yin Cheung, Gary Man-Kit Tse · 2017 · Breast Cancer Research and Treatment
61. Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors
    Antonio Marchetti, Massimo C.P. Barberis, Renato Franco, Graziano De Luca, Maria Vittoria Pace, Stefania Staibano, Marco Volante, Fiamma Buttitta, Elena Guerini‐Rocco, Luisella Righi et al. · 2017 · Journal of Thoracic Oncology
62. Pediatric Cancer Immunotherapy: Opportunities and Challenges
    Mary Frances Wedekind, Nicholas L. Denton, Chun‐Yu Chen, Timothy P. Cripe · 2018 · Pediatric Drugs
63. Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer
    Yaru Tian, Xiaoyang Zhai, Anqin Han, Hui Zhu, Jinming Yu · 2019 · Journal of Hematology & Oncology
64. Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours?
    Nicolas D. Huyghe, Paméla Baldin, Marc Van den Eynde · 2019 · Gastroenterology report
65. Immunotherapy in endometrial cancer: rationale, practice and perspectives
    Wenyu Cao, Xinyue Ma, Jean Victoria Fischer, Chenggong Sun, Beihua Kong, Qing Hua Zhang · 2021 · Biomarker Research
66. PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma
    Anjelica Hodgson, Elzbieta A. Slodkowska, Achim A. Jungbluth, Stanley K. Liu, Danny Vesprini, Danny Enepekides, Kevin McLughlin Higgins, Nora Katabi, Bin Xu, Michelle R. Downes · 2018 · The American Journal of Surgical Pathology
67. MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways
    Arefeh Zabeti Touchaei, Sogand Vahidi · 2024 · Cancer Cell International
68. Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer
    April A. N. Rose, Marco Biondini, Rafael E. Curiel, Peter M. Siegel · 2017 · Pharmacology & Therapeutics
69. Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment
    David A. Wheeler, Naoko Takebe, Toshinori Hinoue, Katherine A. Hoadley, Maria Cardenas, Alina M. Hamilton, Peter W. Laird, Linghua Wang, Adrienne Johnson, Ninad Dewal et al. · 2020 · Cancer Cell
70. Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma
    Yu, Jiayi, Yan, Junya, Guo, Qian, Chi, Zhihong, Tang, Bixia, Zheng, Bin, Yu, Jinyu, Yin, Ting, Cheng, Zhiyuan, Wu, Xiaowen et al. · 2019 · Clinical Cancer Research
71. A regulatory role for the co-chaperone FKBP51s in PD-L1 expression in glioma
    Paolo D’Arrigo, Michele Russo, Anna Rea, Martina Tufano, Elia Guadagno, Marialaura Del Basso De, Roberto Pacelli, Felix Hausch, Stefania Staibano, Gennaro Ilardi et al. · 2017 · Oncotarget
72. Baseline neutrophilia, derived neutrophil‐to‐lymphocyte ratio (dNLR), platelet‐to‐lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel
    Alessandro Russo, Tindara Franchina, Giuseppina Rosaria Rita Ricciardi, Alessandra Battaglia, Antonino Scimone, Rosa Berenato, Antonio Giordano, Vincenzo Adamo · 2018 · Journal of Cellular Physiology
73. Exosomal PD‐L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies
    Zhou, Kaijian, Guo, Shu, Li, Fei, Sun, Qiang, Liang, Guoxin · 2020 · Frontiers in Cell and Developmental Biology
74. Metabolic characteristics of programmed cell death‐ligand 1‐expressing lung cancer on 18 F‐fluorodeoxyglucose positron emission tomography/computed tomography
    Kazuki Takada, Gouji Toyokawa, Tatsuro Okamoto, Shingo Baba, Yuka Kozuma, Taichi Matsubara, Naoki Haratake, Takaki Akamine, Shinkichi Takamori, Masakazu Katsura et al. · 2017 · Cancer Medicine
75. Radiation-induced PD-L1 expression in tumor and its microenvironment facilitates cancer-immune escape: a narrative review
    Nuo-Han Wang, Zheng Lei, Hao-Nan Yang, Zheng Tang, Mengqi Yang, Ying Wang, Jiang-Dong Sui, YongZhong Wu · 2022 · Annals of Translational Medicine
76. Pan‐cancer analysis of copy number changes in programmed death‐ligand 1 (PD‐L1, CD274) – associations with gene expression, mutational load, and survival
    Jan Budczies, Michael Ludwig Bockmayr, Carsten Denkert, Frederick Klauschen, Stefan Gröschel, Silvia Darb‐Esfahani, Nicole Pfarr, Jonas Leichsenring, Maristela Lika Onozato, Jochen K. Lennerz et al. · 2016 · Genes Chromosomes and Cancer
77. Novel strategies for cancer immunotherapy: counter-immunoediting therapy
    Shaochuan Liu, Qian Sun, Xiubao Ren · 2023 · Journal of Hematology & Oncology
78. Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer
    Maarten Versteven, Johan M.J. Van den Bergh, Elly Marcq, Evelien Smits, Viggo F. Van Tendeloo, Willemijn A. Hobo, Eva Lion · 2018 · Frontiers in Immunology
79. Single Extracellular Vesicle Protein Analysis Using Immuno‐Droplet Digital Polymerase Chain Reaction Amplification
    Jina Ko, Yongcheng Wang, Jonathan Carlson, Angela N. Marquard, Jeremy Gungabeesoon, Alain Charest, David A. Weitz, Mikaël J. Pittet, Ralph Weissleder · 2020 · Advanced Biosystems
80. The Role of Circulating Tumor Cells in the Metastatic Cascade: Biology, Technical Challenges, and Clinical Relevance
    Hassan Dianat‐Moghadam, Mehdi Azizi, Zahra Eslami‐S, Luis Enrique Cortés‐Hernández, Maryam Heidarifard, Mohammad Nouri, Catherine Alix‐Panabières · 2020 · Cancers
81. Chemotherapeutic Treatments Increase PD-L1 Expression in Esophageal Squamous Cell Carcinoma through EGFR/ERK Activation
    Hoi Yan Ng, Jian Li, Lihua Tao, Alfred King-yin Lam, Kwok Wah Chan, Josephine Mun Yee Ko, Valen Zhuoyou Yu, Michael Wong, Benjamin C. Li, Maria Li Lung · 2018 · Translational Oncology
82. The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma
    Thomas B. Powles, Jill Walker, J. Andrew Williams, Joaquim Bellmunt B · 2019 · Cancer Treatment Reviews
83. Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review
    Matthieu Roulleaux Dugage, Elise F. Nassif, Antoîne Italiano, Rastislav Bahleda · 2021 · Frontiers in Immunology
84. Molecular Profiling of Thymoma and Thymic Carcinoma: Genetic Differences and Potential Novel Therapeutic Targets
    Franz Enkner, Bettina Pichlhöfer, Alexandru Zaharie, Milica Krunic, Tina Maria Holper, Stefan Janik, Bernhard Moser, Karin Schlangen, Barbara Neudert, Karin Walter et al. · 2016 · Pathology & Oncology Research
85. Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice
    Beung‐Chul Ahn, Kyoung‐Ho Pyo, Chun-Feng Xin, Dongmin Jung, Hyo Sup Shim, Chang Young Lee, Sung Yong Park, Hong In Yoon, Min Hee Hong, Byoung Chul Cho et al. · 2019 · Journal of Cancer Research and Clinical Oncology
86. NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor Resistance
    Fangfang Liu, Yuxuan Wei, Huan Zhang, Jizong Jiang, Peng Zhang, Qian Chu · 2022 · Frontiers in Oncology
87. Programmed death ligand‐1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder
    Bo Wang, Wenwei Pan, Meihua Yang, Wenjuan Yang, Wang He, Xu Chen, Junming Bi, Ning Jiang, Jian Huang, Tianxin Lin · 2018 · Cancer Science
88. The Role of Immune Checkpoint Inhibitors in Cancer Therapy
    Ahmed Basudan · 2022 · Clinics and Practice
89. Molecular Imaging of Immunotherapy Targets in Cancer
    Emily B. Ehlerding, Christopher G. England, Douglas G. McNeel, Weibo Cai · 2016 · Journal of Nuclear Medicine
90. Product review: Avelumab, an anti-PD-L1 antibody
    Collins, Julie M., Gulley, James L. · 2019 · Human Vaccines &amp; Immunotherapeutics
91. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas
    Christelle Combaz-Lair, Françoise Galateau-Sallé, Anne Mc Leer, Nolwenn Le Stang, Laurence David‐Boudet, M. Duruisseaux, G. Ferretti, Elisabeth M. Brambilla, Serge Lebecque, Sylvie Lantuéjoul · 2016 · Human Pathology
92. Lymphoepithelioma-Like Carcinoma in Liver
    Ismaïl Labgaa, Ashley Stueck, Stephen C. Ward · 2017 · American Journal Of Pathology
93. Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade
    Yanna Lei, Xiaoying Li, Qian Huang, Xiufeng Zheng, Ming Liu · 2021 · Frontiers in Oncology
94. Immunotherapy Comes of Age in Lung Cancer
    Priyanka Khanna, Normand Blais, Pierre-Olivier Gaudreau, Luis Corrales · 2016 · Clinical Lung Cancer
95. Genome-Wide Sequencing of Cell-Free DNA Identifies Copy-Number Alterations That Can Be Used for Monitoring Response to Immunotherapy in Cancer Patients
    Taylor J. Jensen, Aaron Michael Goodman, Shumei Kato, Christopher K. Ellison, Gregory A. Daniels, Lisa Kim, Prachi Nakashe, Erin McCarthy, Amin R. Mazloom, Graham McLennan et al. · 2018 · Molecular Cancer Therapeutics
96. TP53 Mutations Promote Immunogenic Activity in Breast Cancer
    Zhixian Liu, Zehang Jiang, Yingsheng Gao, Lirui Wang, Cai Chen, Xiaosheng Wang · 2018 · Journal of Oncology
97. PKM2 Drives Hepatocellular Carcinoma Progression by Inducing Immunosuppressive Microenvironment
    Tian‐En Li, Shun Wang, Xiaotian Shen, Ze Zhang, Mo Chen, Hao Wang, Ying Zhu, Da Xu, Beiyuan Hu, Ran Wei et al. · 2020 · Frontiers in Immunology
98. Gene-expression profiling to predict responsiveness to immunotherapy
    Nigel Balfour Jamieson, Ajay V. Maker · 2016 · Cancer Gene Therapy
99. Challenging Standard-of-Care Paradigms in the Precision Oncology Era
    Vivek Subbiah, Razelle Kurzrock · 2018 · Trends in cancer
100. Increase in PD-L1 expression after pre-operative radiotherapy for soft tissue sarcoma
     Kirtesh R. Patel, Anthony P. Martinez, John M. Stahl, Suzanna J. Logan, Adam J. Perricone, Matthew Jeffrey Ferris, Zachary S. Buchwald, Mudit Chowdhary, Keith A. Delman, David K. Monson et al. · 2018 · OncoImmunology